key: cord-1036474-2bfvvzev
authors: Vanhulle, Emiel; Provinciael, Becky; Stroobants, Joren; Camps, Anita; Maes, Piet; Vermeire, Kurt
title: Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern
date: 2022-02-02
journal: bioRxiv
DOI: 10.1101/2022.02.02.478775
sha: 5100e23d615b03b38b4e152f1a8b57e8075eccc1
doc_id: 1036474
cord_uid: 2bfvvzev

Despite the efficacy of current vaccines against SARS-CoV-2, the spread of the virus is still not under control, as evidenced by the ongoing circulation of the highly contagious SARS-CoV-2 Omicron variant. Basic and antiviral research on SARS-CoV-2 relies on cellular assays of virus replication in vitro. In addition, accurate detection of virus-infected cells and released virus particles is needed to study virus replication and to profile new candidate antiviral drugs. Here, by flow cytometry, we detect SARS-CoV-2 infection at single cell level and distinguish infected Vero E6 cells from uninfected bystander cells. Furthermore, based on the viral nucleocapsid expression, subpopulations of infected cells that are in an early or late phase of viral replication can be differentiated. Importantly, this flow cytometric technique complements RT-qPCR detection and can be applied to all current SARS-CoV-2 variants of concern, including the highly mutated Omicron variant. Method summary This study describes the characterization of SARS-CoV-2 infected cells using intracellular flow cytometric viral nucleocapsid staining that complements RT-qPCR quantification of viral RNA. The technique makes it possible to distinguish between infected cells in the early (low N) or late phase (high N) of viral replication. It can also be applied to the different variants of concern of SARS-CoV-2, including the Omicron variant.

Germany), respectively (Table 1) European Commission, Cat. n° EURM-019) was used as a standard to quantitatively 136 measure viral copy numbers. 137

Total RNA was extracted from cell culture supernatants using QIAamp viral RNA mini 138 kit (Qiagen) following manufacturer's instruction. Viral E and N genes are 139 simultaneously amplified and tested using a multiplex RT-qPCR. All the procedures 140 follow the manufacturer's instructions of the Applied Biosystems TaqMan Fast Virus 141 one-step mastermix (ThermoFisher). Briefly, a 20 µl reaction mix was set up containing 142 5 µl of template, 7 µl of dH2O, 1.5 µl of each combined primer/probe mix (final 143 concentrations of 500 and 250 nM, respectively) and 5 µl of 4X TaqMan Fast Virus 1-144 step mastermix (ThermoFisher). The qPCR plate was sealed and read in the FAM and 145 HEX channels using a QuantStudio™ 5 Real-Time PCR system (ThermoFisher) under 146 the following cycling protocol: 50°C for 5 min (reverse transcription), 95°C for 20 147 seconds (DNA polymerase activation), followed by 45 cycles of 95°C for 3 seconds 148 (denaturation) and 55°C for 30 seconds (annealing and fluorescence collection) 149 followed by an infinite 4°C hold. 150 (ACE2) receptor (7) and subsequent virus entry in the cell. In contrast, the antibody 182 R007, that also binds to the S protein but in a non-neutralizing manner, lacked antiviral 183 potency (Figure 1) . 184

As CPE monitoring and scoring is a fairly subjective evaluation method, we next 185 implemented a highly sensitive RT-qPCR method for the objective quantification of 186 virus infection and virion production. To preserve the detection capacity of our assay 187 for emerging SARS-CoV-2 mutants, we chose the simultaneous detection of two genes 188 in the viral genome, i.e., the gene encoding for the highly abundant nucleoprotein N 189 and that for the envelope protein E (Figure 2A) . The primer sequences were selected 190 to target conserved regions of the viral genome (for details see Table 1 ). Primer and 191 probe sequences for N2 were obtained from Centers for Disease Control and 192 Prevention (CDC, USA), whereas the sequences for E were from Charité (Berlin, 193 Germany). In order to perform a duplex RT-qPCR, probes with matching fluorescent 194 dyes (i.e., FAM and HEX) were designed accordingly. As proof of principle, we first 195 validated our duplex RT-qPCR assay on a dilution series of a SARS-CoV-2 viral stock. RT-qPCR. To assess if there was successful replication of the virus, we compared the 207 samples with the virus input, i.e., the diluted virus stock solution to which the cells were 208 exposed to for 2 hours. Also, we collected the wash sample (after the removal of virus 209 input) that represents the amount of residual virus particles that were attached to the 210 cells 'aspecifically' without productive viral entry in the cell, to determine the lower limit 211 of detection of our virus yield assay. As shown in Figure 2D , Vero E6 cells were 212 successfully infected with SARS-CoV-2 with productive virus release in the 213 supernatant ('Control'), as evidenced by the high copy numbers of viral RNA that 214 exceeded the virus input. Treatment with antibody R001 completely abolished virus 215 infection whereas R007 did not exert any antiviral activity, thus, confirming the CPE 216 analysis of Figure 1 . Thus, as comparable data were obtained for both SARS-CoV-2 217 genes, we concluded that we successfully developed a E/N gene duplex RT-qPCR. 218

To examine the robustness of our assay, we next determined the virus yield in Vero 219 E6 cells infected with the different SARS-CoV-2 variants of concern. As summarized 220

in Figure 3 , our duplex RT-qPCR assay was able to simultaneously detect the viral 221 genes E and N from all tested variants, also, from the current circulating Omicron 12 variant. This also demonstrates that the many reported mutations in the different 223 variants seem not to affect the primer binding sites of our assay. Finally, we analyzed the flow cytometric data in more detail. As shown in Figure 6A , CoV-2. Furthermore, this technique makes it possible to distinguish between 319 subpopulations of infected cells that are in an early (low N) or late phase (high N) of 320 viral replication. This can be an added value in the profiling of new candidate antiviral 321 drugs, to discriminate between entry inhibitors and viral polymerase inhibitors that 322 block viral replication. Importantly, this flow cytometric technique complements RT-323 qPCR detection and can be applied to all current SARS-CoV-2 variants of concern, 324 including the highly mutated Omicron variant. We believe that this method will be a 325 valuable supplement for the ongoing study of COVID-19. i.e., the Spike protein (S), the Envelope protein (E), the Membrane protein, and the 379 Nucleocapsid protein (N). The genes for E and N were selected for RT-qPCR 380

A familial cluster 329 of pneumonia associated with the 2019 novel coronavirus indicating person-to-person 330 transmission: a study of a family cluster

A new coronavirus 332 associated with human respiratory disease in China

RNA based mNGS approach 334 identifies a novel human coronavirus from two individual pneumonia cases

Wuhan outbreak

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

A Simple Method of Estimating Fifty Per Cent Endpoints12

EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020

The SARS-CoV-2 Nucleocapsid Protein and Its Role 350 in Viral Structure

SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final 354

Virus entry by macropinocytosis

SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug 359 discovery and development

(1:10) of a SARS-CoV-2 (20A.EU2 variant) virus stock was measured by duplex qPCR for E and N gene (RNA) copy numbers, starting from a 10 3 x dilution. Graph 383 shows amplification plot for 2 technical replicates of each sample. Insert shows the 384 standard curve for the N and E gene RNA standards. C) Samples from (B) were 385 analyzed for the quantification of copy numbers of E and N (mean ± SD, n = 2). D) RT-386 qPCR analysis of the samples from Figure 1 . Vero E6 cells were exposed to SARS-387CoV-2 (20A.EU2 variant; MOI = 0.015) for 2h. Supernatant (= virus input) was then 388 removed, and cells were washed in PBS (= wash) and given fresh medium. In the 389 conditions with the antibody-treatment (R001 or R007), 2.5 µg/ml of antibody was 390 administered together with the virus, and administered again after the wash step. At variants of concern. Vero E6 cells were exposed to a fixed virus stock dilution (10x) 401 of different variants of concern of SARS-CoV-2 (as indicated). After a 2 h incubation,